Close Menu
Gulf Newsbreak
    What's Hot

    U.S. Polo Assn. Supports Star-Studded ‘Boo-Yah’ Night for The V Foundation for Cancer Research

    December 7, 2023

    Transform Your Holiday Health: Cogno-Cravings Unveils Breakthrough Solution for Holiday Cravings and Stress

    December 6, 2023

    Nitinotes Surgical in Full Swing: Impressive Board Appointment, Over 90 Patients Treated, 400+ Sutures Performed, and a $10.1M Series B Funding Round Closure

    December 5, 2023
    • Home
    • Contact Us
    Facebook X (Twitter) Instagram
    Gulf NewsbreakGulf Newsbreak
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Gulf Newsbreak
    Health

    Early results of a study on an Alzheimer’s drug show promise

    September 30, 2022
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email Tumblr Reddit VKontakte Telegram

    The shares of Biogen and other drugmakers researching Alzheimer’s disease surged Wednesday after Japan’s Eisai Co. Ltd.. reported its potential treatment appeared to slow the disease in a late-stage study. Lecanemab, the drugmaker’s treatment, reduced patients’ clinical decline by 27% after 18 months of infused treatment compared to placebos or fake drugs, according to AP reports.

    Early results of a study on an Alzheimer's drug show promiseThe results of Eisai’s global study of nearly 1,800 people with early-stage Alzheimer’s were announced late Tuesday. Mental decline and ability to do daily activities such as dressing and eating were measured using a scale. Eisai Co. Ltd. said it would present full research results at a conference in late November. The findings will also be published in a peer-reviewed medical journal.

    The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Biogen and Eisai will jointly promote the drug. Researchers usually caution against evaluating a study before full results are released. According to Mizuho Securities analyst Graig Suvannavejh, the initial findings are “quite robust” and support regulatory approval.

    According to the Alzheimer’s Association, the findings provide the highest hope so far for treating the disease’s underlying causes. Alzheimer’s disease affects some 6 million Americans and many more worldwide, gradually destroying parts of the brain that control memory, reasoning, communication, and basic daily functions.

    There is no known cure for Alzheimer’s disease. Researchers are still trying to understand what causes the disease, and long-standing treatments only manage symptoms. It has been nearly two decades since Biogen introduced a new Alzheimer’s drug. However, it has generally flopped after debuting at $56,000 annually, which Biogen later reduced. Due to weak evidence that the drug slows Alzheimer’s progression, doctors have been hesitant to prescribe it. Due to the drug’s high price and uncertain benefits, insurers have blocked or restricted coverage.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    Related Posts

    Revolutionizing diabetes care with saliva tests replacing finger pricks

    December 5, 2023

    Start your day right with complex carbs to enhance weight loss and blood sugar control

    December 5, 2023

    New insights into natural remedies for heart health

    December 2, 2023

    Maximizing your diet with prunes and plums

    November 28, 2023

    Weekend workouts equally effective as daily routines, new study finds

    November 27, 2023

    Physical activity mitigates cognitive deficits caused by lack of sleep

    November 27, 2023
    Latest News

    Revolutionizing diabetes care with saliva tests replacing finger pricks

    December 5, 2023

    A revolutionary breakthrough in diabetes management is on the horizon, as scientists from Canada and…

    Economic uncertainty spurs unprecedented demand for gold.

    December 5, 2023

    New York, L.A., and San Francisco among the world’s most expensive

    December 5, 2023

    Shaping tomorrow’s technology today with the top 11 companies leading the AI revolution

    December 5, 2023

    Start your day right with complex carbs to enhance weight loss and blood sugar control

    December 5, 2023
    Business

    Economic uncertainty spurs unprecedented demand for gold.

    December 5, 2023

    Innovative construction solutions unveiled at Dubai’s Big 5 Global

    December 5, 2023

    Global oil dynamics shift as OPEC+ agrees on 2 million bpd cut

    December 2, 2023
    News

    New York, L.A., and San Francisco among the world’s most expensive

    December 5, 2023

    $9 billion boost from Global Fund for climate-impacted health systems

    December 5, 2023

    UAE and Mongolia strengthen ties with strategic agreements in Abu Dhabi

    December 1, 2023
    Travel

    Air Arabia broadens horizons with direct flights to Phuket

    November 29, 2023

    Etihad Airways elevates Grand Prix with spectacular 20th anniversary fly-past

    November 29, 2023

    Finland blazes a trail with the world’s first digital passport system

    October 3, 2023
    © 2022 Gulf Newsbreak | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.